(2024)
In Vitro Activity of Benzimidazole (SPR719) Against Clinical Isolates of Nontuberculous Mycobacteria With and Without Clarithromycin or Amikacin Resistance.
ANNALS OF LABORATORY MEDICINE.
44,
1
(2023)
Oral β-lactam pairs for the treatment of Mycobacterium avium complex pulmonary disease.
JOURNAL OF INFECTIOUS DISEASES.
-,
-
(2023)
Spontaneous Cultural Conversion Rate of Mycobacterium avium Complex Pulmonary Disease Based on BACES Severity.
JOURNAL OF CLINICAL MEDICINE.
12,
22
(2023)
Changes in sputum microbiota during treatment for nontuberculous mycobacterial pulmonary disease.
SCIENTIFIC REPORTS.
13,
1
(2023)
Outcomes of Intermittent Multidrug IV Therapy for Refractory Mycobacterium abscessus Pulmonary Disease.
CHEST.
12,
23
(2023)
Clinical Characteristics and Treatment Outcomes of Mycobacterium fortuitum Pulmonary Disease.
MICROBIOLOGY SPECTRUM.
11,
4
(2023)
Performance Evaluation of MolecuTech REBA Myco-ID Using HybREAD480 for Identification of Nontuberculous Mycobacteria.
CLINICAL LABORATORY.
69,
7
(2023)
The lung microbiota in nontuberculous mycobacterial pulmonary disease.
PLOS ONE.
18,
5
(2023)
In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, including Macrolide-/Amikacin-Resistant Clinical Isolates..
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY.
65,
5
(2023)
Performance Evaluation of the BACTEC MGIT 960 System for Rifampin Drug-Susceptibility Testing of Mycobacterium tuberculosis Using the Current WHO Critical Concentration.
JOURNAL OF CLINICAL MICROBIOLOGY.
61,
1
(2022)
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
LANCET.
400,
10362
(2022)
Outcomes of Short-Term Tigecycline-Containing Regimens for Mycobacterium abscessus Pulmonary Disease.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY.
66,
10
(2022)
Clinical utility of EBUS-TBNA of hilar, interlobar, and lobar lymph nodes in patients with primary lung cancer.
THORACIC CANCER.
13,
17
(2022)
Impact of Time Between Diagnosis and Treatment for Nontuberculous Mycobacterial Pulmonary Disease on Culture Conversion and All-Cause Mortality.
CHEST.
161,
5
(2022)
Impact of Time Between Diagnosis and Treatment for Nontuberculous Mycobacterial Pulmonary Disease on Q9 Culture Conversion and All-CauseMortality.
CHEST.
3692,
21
(2022)
Treatment outcomes of Mycobacterium avium complex pulmonary disease according to disease severity.
SCIENTIFIC REPORTS.
12,
1
(2022)
Developing a Diagnostic Bundle for Bronchiectasis in South Korea: A Modified Delphi Consensus Study.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE.
85,
1
(2021)
In Vitro Activity and Clinical Outcomes of Clofazimine for Nontuberculous Mycobacteria Pulmonary Disease.
JOURNAL OF CLINICAL MEDICINE.
10,
19
(2021)
Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease.
CHEST.
160,
2
(2021)
In Vitro Activity of Oxazolidinone against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY.
65,
7
학술회의논문
(2023)
Comparison of the Sputum Microbiome Between Stable Nontuberculous Mycobacteria Pulmonary Disease Patients and Those Requiring Antibiotic Treatment.
KATRD International Conference 2023.
대한민국
